{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:30:56Z","timestamp":1782307856457,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jgo.2026.102959","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:33:55Z","timestamp":1774650835000},"page":"102959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world patterns of maintenance therapy after allogeneic transplant in older adults with acute myeloid leukemia: A Medicare cohort study"],"prefix":"10.1016","volume":"17","author":[{"given":"Vanessa E.","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nimke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kardel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priti","family":"Pednekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgo.2026.102959_bb0005","author":"Surveillance Research Program, National Cancer Institute"},{"key":"10.1016\/j.jgo.2026.102959_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cncr.33873","article-title":"Frontline treatment patterns and outcomes among older adults with acute myeloid leukemia: a population-based analysis in the modern era","volume":"128","author":"Kennedy","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2026.102959_bb0015","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","article-title":"Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States","volume":"130","author":"Muffly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2026.102959_bb0020","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jgo.2026.102959_bb0025","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102959_bb0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jgo.2026.102959_bb0035","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2026.102959_bb0040","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2026.102959_bb0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41409-023-01979-5","article-title":"A novel risk model for predicting early relapse in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem-cell transplantation","volume":"58","author":"Yuan","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jgo.2026.102959_bb0050","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","article-title":"Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia","volume":"56","author":"Maziarz","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jgo.2026.102959_bb0055","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102959_bb0060","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","article-title":"Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial","volume":"21","author":"Xuan","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jgo.2026.102959_bb0065","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2026.102959_bb0070","series-title":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Acute Myeloid Leukemia Version 3.2026-November 24, 2025","year":"2025"},{"key":"10.1016\/j.jgo.2026.102959_bb0075","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.jtct.2021.01.001","article-title":"Impact of polypharmacy prior to allogeneic hematopoietic stem cell transplantation in older adults","volume":"27","author":"Sugidono","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jgo.2026.102959_bb0080","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.bbmt.2020.08.031","article-title":"Use of potentially inappropriate medications in older allogeneic hematopoietic cell transplantation recipients","volume":"26","author":"Bhargava","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jgo.2026.102959_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.612880","article-title":"FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies","volume":"10","author":"Kennedy","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jgo.2026.102959_bb0090","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01290","article-title":"A systematic review of medication adherence thresholds dependent of clinical outcomes","volume":"9","author":"Baumgartner","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jgo.2026.102959_bb0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0260358","article-title":"Providers' mediating role for medication adherence among cancer survivors","volume":"16","author":"Trogdon","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.jgo.2026.102959_bb0100","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3324\/haematol.2017.186346","article-title":"Allogeneic stem cell transplantation for FLT3 mutated acute myeloid leukemia in first complete remission: does age really matter?","volume":"103","author":"Ciurea","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jgo.2026.102959_bb0105","series-title":"XOSPATA\u00ae (gilteritinib) tablets, for oral use [package insert]","year":"2018"},{"key":"10.1016\/j.jgo.2026.102959_bb0110","series-title":"RYDAPT\u00ae (midostaurin) capsules, for oral use [package insert]","year":"2021"},{"key":"10.1016\/j.jgo.2026.102959_bb0115","series-title":"NEXAVAR (sorafenib) tablets, for oral use [package insert]","year":"2020"},{"key":"10.1016\/j.jgo.2026.102959_bb0120","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000545384","article-title":"Streamline: retrospective cohort study of FMS-like tyrosine kinase 3-mutated acute myeloid leukemia - real-world treatment patterns and clinical outcomes of patients in first relapse or refractory diagnosis","volume":"149","author":"Zeidan","year":"2026","journal-title":"Acta Haematol"},{"key":"10.1016\/j.jgo.2026.102959_bb0125","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jgo.2026.102959_bb0130","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1080\/10428194.2025.2561737","article-title":"Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data","volume":"66","author":"Kennedy","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jgo.2026.102959_bb0135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.15027","article-title":"Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities","volume":"180","author":"Lin","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2026.102959_bb0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jgo.2014.04.004","article-title":"Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates","volume":"5","author":"Holmes","year":"2014","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.jgo.2026.102959_bb0145","doi-asserted-by":"crossref","first-page":"e949","DOI":"10.1093\/oncolo\/oyac147","article-title":"Adherence to oral treatments in older patients with advanced prostate cancer, the ADHERE study: a prospective trial of the meet-URO network","volume":"27","author":"Rescigno","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jgo.2026.102959_bb0150","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1177\/10781552221103547","article-title":"Adherence to oral anti-cancer therapies in older patients is similar to that of younger patients","volume":"29","author":"Lory","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jgo.2026.102959_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J077v22n02_01","article-title":"Survival of patients who have undergone allogeneic bone marrow transplantation: the relative importance of in-hospital lay care-partner support","volume":"22","author":"Foster","year":"2004","journal-title":"J Psychosoc Oncol"},{"key":"10.1016\/j.jgo.2026.102959_bb0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/hematology.2021000257","article-title":"Allogeneic hematopoietic cell transplantation for older patients","volume":"1","author":"Lin","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jgo.2026.102959_bb0165","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41409-022-01650-5","article-title":"Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis","volume":"57","author":"Maakaron","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jgo.2026.102959_bb0170","doi-asserted-by":"crossref","first-page":"683.e1","DOI":"10.1016\/j.jtct.2024.04.016","article-title":"Clinical outcomes and treatment patterns in adults with FLT3-ITD(Mut+) acute myeloid leukemia undergoing allogeneic hemopoietic cell transplantation in the United States and Canada","volume":"30","author":"Pandya","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jgo.2026.102959_bb0175","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1177\/10781552211043525","article-title":"Evaluation of a patient self-medication program in allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Polito","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jgo.2026.102959_bb0180","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/10781552211073469","article-title":"Can pharmacotherapeutic follow-up after allogeneic hematopoietic stem cell transplantation improve medication compliance?","volume":"29","author":"Zanetti","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jgo.2026.102959_bb0185","first-page":"3491","article-title":"Improving the transition of highly complex patients into the community: impact of a pharmacist in an allogeneic stem cell transplant (SCT) outpatient clinic","volume":"21","author":"Chieng","year":"2013","journal-title":"Support Care Cancer"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682600113X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187940682600113X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:04:12Z","timestamp":1777593852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187940682600113X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S187940682600113X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102959","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world patterns of maintenance therapy after allogeneic transplant in older adults with acute myeloid leukemia: A Medicare cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2026.102959","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102959"}}